Valneva (NASDAQ:VALN) Shares Gap Down to $7.71

Valneva SE (NASDAQ:VALN) shares gapped down before the market opened on Monday . The stock had previously closed at $7.71, but opened at $7.54. Valneva shares last traded at $7.56, with a volume of 1,038 shares.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on VALN. HC Wainwright reissued a “buy” rating and set a $26.00 price objective on shares of Valneva in a research note on Thursday, March 21st. Guggenheim dropped their price objective on Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, March 22nd.

Valneva Trading Down 2.7 %

The business has a 50 day simple moving average of $7.67 and a 200-day simple moving average of $9.34. The company has a current ratio of 1.65, a quick ratio of 1.37 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $522.29 million, a price-to-earnings ratio of -4.75 and a beta of 2.22.

Valneva (NASDAQ:VALN) last released its earnings results on Wednesday, March 20th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.70). The company had revenue of $45.12 million during the quarter, compared to analysts’ expectations of $45.06 million. Valneva had a negative net margin of 65.99% and a negative return on equity of 59.48%. On average, equities analysts predict that Valneva SE will post 0.11 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. increased its holdings in shares of Valneva SE (NASDAQ:VALN) by 2.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 354,361 shares of the company’s stock after purchasing an additional 9,361 shares during the period. General American Investors Co. Inc. owned 0.51% of Valneva worth $2,831,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.